David Mantus, Ph.D. is President, US Operations at Pulmocide. Prior to joining Pulmocide he was Chief Development Officer, and Managing Director, Arsanis Biosciences GmbH, at Arsanis, Inc. He has more than 28 years of drug development experience, including clinical, regulatory and manufacturing successes. for programs in endocrinology, central nervous disorders, and infectious disease. His work in infectious disease product development has included small molecules, microbiome-based therapeutics, immune globulins, monoclonal antibodies, and vaccines. Dr. Mantus has led teams responsible for all aspects of product development, from pre-IND through global commercialization and partnering. Prior to Arsanis he held leadership roles in development at Seres Health, Cubist Pharmaceuticals, Shire Biologics, and Procter & Gamble Pharmaceuticals.
Dr. Mantus received his M.S. and Ph.D. in Chemistry from Cornell University and was a post-doctoral research fellow in Biomedical Engineering at the Un
Dr. Mantus received his M.S. and Ph.D. in Chemistry from Cornell University and was a post-doctoral research fellow in Biomedical Engineering at the Un
Speaking In
[Available On-Demand]
Phase 3 respiratory company with novel anti-fungal therapy for invasive aspergillosis patients…